Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

abacavir-dolutegravir-lamiVUDine

abacavir-dolutegravir-lamiVUDine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Triumeq TABLET, ORAL 600 mg-50 mg-300 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

NOTES

abacavir-dolutegravir-lamiVUDine (Triumeq)                                                                

  • 600 mg-50 mg-300 mg tablet once Daily

abacavir (Ziagen) AND dolutegravir (Tivicay) AND lamiVUDine (Epivir)

  • ONE 600 mg abacavir tablet PLUS ONE 50 mg dolutegravir tablet PLUS ONE 300 mg lamiVUDine tablet

 

Give at same strength and dosing interval as Triumeq

Triumeq medication guide

Triumeq is classified as non-formulary, not stocked.  Interchange to individual ingredients dispensed separately.

Reviewed: November 18, 2014 (Triumeq)

Last updated: Jun. 29, 2022






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved